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We evaluated the prognostic and predictive value of a range of molecular changes in the setting of a randomised
trial comparing standard PCV (procarbazine, CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) and vincristine)
chemotherapy with the standard temozolomide (TMZ) 5-day (200 mg/m2/day) schedule and a 21-day (100 mg/m2/day)
schedule in chemo-naïve, high-grade glioma (non-oligodendroglial tumours; WHO (World Health Organisation) grades III
and IV) patients at first progression following radiotherapy.
354 samples (79.2%) from the first operation of the 447 randomised patients provided enough tumour DNA for
some or all parts of the study. Genome-wide array comparative genomic hybridisation (aCGH), mutation analysis
of IDH1/2 and TP53 and methylation analyses of the MGMT CpG-island was done.
84% of grade III tumours and 17% of grade IV had IDH1 or IDH2 mutations that conferred a better prognosis in
both; MGMT methylation (defined as average value across 16 CpGs ≥ 10%) occurred in 75% of tumours and was
also associated with improved survival. Both were of independent prognostic value after accounting for clinical
factors and tumour grade. None of the molecular changes investigated gave clear evidence of a predictive benefit
of TMZ over PCV or 21-day TMZ over 5-day TMZ although power was limited and a role for MGMT methylation
could not be ruled out. Loss of 1p and 19q was seen in only 4 patients although hemizygous loss of 1p36 occurred
in 20%.
The findings support reports that IDH1/2 mutations and MGMT methylation can be used in addition to tumour
grade and clinical factors to predict survival in patients with recurrent high grade gliomas when treated with any
of the therapy regimes used.
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Randomised clinical trials provide a basis for successful
evaluation of biomarkers. To date methylation of the O6-
methylguanine-DNA methyltransferase (MGMT) gene is
the only molecular marker that can be mechanistically
linked to a response to alkylating agent chemotherapy.
MGMT promoter methylation with resultant decreased ex-
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unless otherwise stated.the repair of DNA damage caused by alkylating agents. In
an EORTC trial of temozolomide in the primary treatment
of glioblastoma [1]MGMT methylation status was strongly
prognostic for survival, and with a suggestion of a predict-
ive effect [2] although this remains unproven within that
trial. Other studies [2,3] have also shown MGMT methy-
lation to be prognostic in glioblastoma patients given
chemoradiotherapy [4,5]. More recently studies in elderly
and poor prognosis patients with glioblastoma testing
chemotherapy alone against radiotherapy with or without
chemotherapy demonstrated predictive value of MGMT
methylation status (Wick et al. [5] (NA08), Malmstrom
et al. [6]). On current evidence the predictive value appears
confined to this patient population. However, the value ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with PCV (Procarbazine, CCNU and Vincristine), a recog-
nised effective regimen in the treatment of recurrent high
grade glioma used as standard therapy prior to the intro-
duction of temozolomide. While both Procarbazine, and
CCNU are also alkylating agents, it is possible that MGMT
methylation status might be differentially predictive of
response to temozolomide over PCV.
We therefore evaluated the prognostic and predictive
value of a range of molecular changes reported for adult
brain tumours in the setting of a randomised trial in
chemo-naïve, recurrent high-grade astrocytic gliomas
(WHO grades III and IV) including anaplastic astrocytoma
(AA), anaplastic oligoastrocytoma (AOA), glioblastoma
(GB) and gliosarcoma (GS) following previous radiother-
apy, comparing PCV (procarbazine, CCNU and vincris-
tine) chemotherapy with two temozolomide schedules; the
standard 5-day (200 mg/m2/day) schedule and a 21-day
(100 mg/m2/day) schedule. The results of this trial have
been published elsewhere [7]. The molecular characteris-
tics of the tumours analysed included 1p and 19q copy
number status, originally considered a prognostic marker
in oligodendroglial tumours but more recently shown to
be predictive in patients with anaplastic oligodendrogli-
oma [8,9], MGMT copy number and methylation status
and IDH1 or IDH2 mutation, all reported to be prognostic
biomarkers [1,2,10-12]. In addition other genetic abnor-
malities frequently reported in these tumour types were
also analysed. The sub-randomisation between 5-day and
21-day schedules in this trial also provided a framework
for the investigation of the hypothesis that higher intensity
of temozolomide treatment might be required for a re-




Patients were drawn from the 447 patients with recurrent
high grade glioma randomised into the MRC BR12 trial
[7] who consented to the use of their formalin fixed paraf-
fin embedded tumour samples for central review and
further research. The trial was ethically approved and
written informed consent was obtained from all patients.
Eligible patients for the trial were chemo-naïve adults of
either sex with histologically verified AA, GB, AOA or GS
(WHO grade III/IV at diagnosis, relapse or transform-
ation) who had undergone primary treatment including
radiotherapy completed >2 months before randomisation,
had evidence of progression confirmed by evaluable en-
hancing recurrent tumour on contrast enhanced MRI/CT
within the 2 weeks prior to start of treatment, and were
considered fit for chemotherapy. A central review of path-
ology data followed the 4th edition of the WHO Classifi-
cation of Tumours of the Central Nervous system [13].Tumour tissue
Tumour tissue was required from the first diagnosis of a
high grade tumour and was ‘micro-dissected’ from sec-
tions from the blocks taken at the time of the original
surgery in most cases. In a small number of cases blocks
were also available from diagnostic material resected at
recurrence. The commonest cause of a case failing the
molecular analysis was the available tissue blocks consist-
ing of few well-preserved tumour cells with widespread
necrosis.
DNA isolation and genome-wide copy number analysis
Tumour DNA was isolated using QIAamp DNA micro kit
(Qiagen, Cat 56304) from micro-dissected (often multiple)
10 μm sections from the paraffin blocks of each case
avoiding normal tissue and necrosis. Genome wide copy
number data was obtained by array comparative genomic
hybridization using a custom tiled path array of chro-
mosome 1 and 19 incorporated into a 1 Mb genome-wide
array with additional probes for genes of interest as previ-
ously described [14,15]. The copy number status of the
following regions were scored for statistical analyses:
Chromosome 1 (particularly total 1p loss and localised
1p36 loss), chromosome 7, chromosome 10, chromosome
13, and chromosome 19 (particularly total 19q loss).
Genes of particular interest where copy number was re-
ported separately included EGFR, CDKN2A/B and p14ARF,
MDM2, CDK4, RB1 and PDGFRA, PTEN andMGMT.
Mutation analysis of IDH1, IDH2 and TP53 and MGMT
methylation analysis
Pyrosequencing of exon 4 of IDH1 was done and if no
mutation was found exon 4 of IDH2 was also pyrose-
quenced [16]. The PCR primers used were as follows:
IDH1 Forward primer CAAAAATATCCCCCGGCTTG,
with reverse primer bio-CAACATGACTTACTTGATC
CCC and for IDH2 ACATCCCACGCCTAGTCCC with
reverse primer bio-TCTCCACCCTGGCCTACCTG. Sin-
gle stranded templates were prepared using a PyroMark
Vacuum Prep Workstation (Qiagen, Crawley, UK) as per
manufacturer’s recommendations. Briefly 40 μl of the PCR
product was mixed with 3 μl of Streptavidin Sepharose
Beads (GE Healthcare, Little Chalfont, UK) and 37 μl of
Binding buffer (Qiagen, Crawley, UK) binding the bio-
tinylated DNA to the sepharose beads followed by de-
naturation and the removal of the non-biotinylated strand
and annealing to 1.5 picomole of the pyrosequencing
primer in the annealing buffer (Qiagen, Crawley, UK). The
pyrosequencing primer for IDH1 was TGGGTAAAACC
TATCATCATA and for IDH2 CCAAGCCCATCACCA
TTG. Pyrosequencing was performed using PyroGold
SNP Reagents and PyroMark software on a PyroMark
ID pyrosequencer (Qiagen, Crawley, UK) as recom-
mended. The system interrogated the 1st (c.394) and
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and the 1st (c.514) and 2nd (c.515) nucleotides of codon
172 (Arg) in IDH2.
TP53 mutation analysis [17] was carried out by individ-
ual PCR amplification of each of exons 4 to 10 followed
by direct sequenceing using the Applied Biosystems
BigDye Terminator v3.1 cycle sequencing Kit (Life
Technologies) on an ABI PRISM 3100-Avant Genetic
Analyser (Life Technologies) [18].
Methylation analysis of the MGMT promoter was by
bisulfite modification of approximately 500 ng genomic
DNA using the EZ DNA Methylation Kit (ZYMO Re-
search, Orange, CA 92867 U.S.A., Cat D5001) followed
by PCR using a forward primer GTTTYGGATATGT
TGGGATAG and a biotinylated reverse primer bio-AAA
ACCACTCRAAACTACCAC in a 50 μl reaction includ-
ing 2.5 mM MgCl2, 250 μM each dNTP and 1.25 units
of Thermo-Start DNA polymerase (Thermo Scientific,
Loughborough, UK) for map of region see Figure 1.
Amplification of the 166 bp product was confirmed by
agarose gel electrophoresis. Single stranded templates
were prepared as described above for the IDH1/2 muta-
tion analysis. Two assays were run on this template
using the following two pyrosequencing primers: GATA
GTTYGYGTTTTTAGAA to analyze, YGTTTTGYGTT
TYGAYGTTYGTAGGTTTTYGYGGTGYGTATYGTT
TGYGA, dispensation order ATCGTTAGTCTGTTC
GTATCAGTCGTCATGTTCAGTCGTAGTCGTGATCG
TAGTCG; and GYGATTTGGTGAGTGTTTG to analyze,
GGTYGTTTYGTTTTYGGAAGAGTGYGGAGTTTTT
TTTYGGGAYGG, dispensation order AGTCTGTTC
AGTTCGAGAGTAGTCGATGCTTCGTATC. PyroGold
Q96 SQA reagents and the PyroMark ID pyrosequencerFigure 1 Map of the 3’ end of the MGMT CpG island, showing the Cp
some other studies as well as part of exon 1 of MGMT.(Qiagen, Crawley, UK) were used and the data were ana-
lyzed using Pyro Q-CpG software reporting% methy-
lation at each of the 16 CpGs [19,20]. This analysis
encompasses all MSP CpGs as studied by Stupp et al. and
Hegi et al. [1,2].
Statistical methods
Associations between markers and clinical variables were
quantified using the χ2 test of association or Fisher’s exact
test for categorical variables, and t-test to compare mean
age across different types of abnormalities. The primary
outcome measure for assessment of prognostic and pre-
dictive markers was survival, calculated from the date of
randomisation into the main trial to the date of death, or
date last known to be alive. Sample size was dictated by
the availability of samples in trial patients, but conserva-
tive a priori sample size calculations based on obtaining
samples for 235 patients (with 213 events) would give over
80% power to detect a hazard ratio of 0.6 for a marker
with 50% prevalence at a 2-sided significance level of 1%.
Kaplan-Meier survival curves were compared using the
log rank test and potential prognostic markers were fitted
into a Cox regression survival model containing baseline
clinical characteristics (age, gender, tumour grade (AA vs
GB), and WHO performance status) to look for evidence
of independent prognostic importance. χ2 tests for hetero-
geneity were used to assess evidence that marker status
was predictive of treatment effect (TMZ vs PCV and
5-day TMZ vs 21-day TMZ acknowledging that power
for the latter comparison was substantially reduced),
or showed evidence of interaction with tumour grade.
MGMT methylation was initially averaged across all 16
CpGs and considered as a binary variable as in previousGs analysed in this study (74–89) and the regions examined in
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quent exploratory analyses looked at individual CpG
data as continuous variables for their prognostic and
predictive value using Cox regression survival models
with fractional polynomials to allow for non-linear asso-
ciations with survival [21]. The family of degree-one frac-
tional polynomials (which include log (x) and x2) were
used. To assess the robustness of the results, in the
absence of an independent data set, bootstrap resampling
methods were used taking bootstrap samples with 100
replicates. These analyses were carried out in all patients,
and repeated in the subset hemizygous for MGMT in
whom methylation% represents a single value rather than
an average across both copies of the gene. They were
again repeated in the GB patients only.
Results
Pathological review and access to formalin fixed paraffin
embedded tissue
Of 447 patients randomised into BR12, sections or
blocks containing tumour were received from 354 (79%).
The two major reasons why tumour tissue was not avail-
able for the translational study were: a) consent for this
part of the trial not obtained or refused (39 patients; 9%
of all cases) and b) Histopathology Departments declin-
ing to release or unable to retrieve tissue (48 cases; 11%
of all cases).
Material sufficient for central pathology review and
some molecular analysis was possible on 314 patients
(87% of patients with material, 70% of randomised pa-
tients). Five patients were deemed ineligible, 3 gliosar-
comas have been included among the glioblastomas. In
cases that had been re-operated and where there were
multiple specimens (n = 8) some of whom showed
progression, the first WHO grade III or IV was used
to determine tumour grade in that patient. Of the 309
eligible cases from whom material was received, successful
analysis for aCGH, MGMT methylation and IDH1/2 mu-
tation was possible in 267, 281 and 282 cases respectively;
successful analysis for all parts of the study was possible in
236 (53% of randomised patients). Comprehensive analysis
of exons 4–10 of TP53 was, however, only successful
in 82 cases, while incomplete data were obtained in a
further 186.
Representativeness of samples
Patient characteristics and survival in patients with and
without tumour samples sufficient for analysis of MGMT
methylation and IDH1/2 respectively were compared;
the only systematic difference was the extent of resec-
tion at initial surgery, the proportion of patients with
biopsy alone being higher in the group for whom
MGMT methylation and IDH1/2 analysis was not pos-
sible (e.g. 39% vs. 18% in patients where methylationanalysis was possible). However, there was no clear differ-
ence in overall survival between the patients who were in-
cluded in the MGMT methylation analyses and those who
were not (HR = 0.97, 95% CI (0.78-1.21)) and this result
was similar for the IDH1 analysis (HR = 0.86, 95% CI
(0.69-1.07)).
Frequency of copy number abnormalities
Array CGH was successful in 267 eligible cases including
6 AOA, 36 AA and 225 GB. Copy number abnormalities
are tabulated by tumour type/grade in Table 1.
Total loss of one copy of each of 1p and 19q was seen
in only 4 patients overall 1.5%, 95% CI (0.4-3.8%) and
included 1/6 AOAs, 1/36 AAs and 2/225 GBs. The AOA
and the AA with total loss of one copy of each of 1p and
19q both also had a mutation of IDH1 (R132H) and
marked methylation of all the 16 MGMT CpGs assayed.
The data set for the 2 GBs was not complete. The other
common region lost on 1p was limited to the 1p36
region. Hemizygous loss of this region was seen in 4/36
AAs 11.1%, 95% CI (3.1 - 26.1%) and 49/225 GBs 21.8%,
95% CI (16.6 – 27.7%) with a further 6 GBs (2.7%) show-
ing homozygous deletion of 1p36.
Copy number of the following genes were documented
on the tailored array by the use of specific probes
(EGFR, CDKN2A, CDKN2B, p14ARF, MDM2, CDK4,
RB1 and PDGFRA). Amplification of the 4q12 region
encompassing the PDGFRA gene was seen only in ana-
plastic astrocytomas (3/36; 8%) and glioblastomas (14/225;
6%). The following copy number abnormalities were
all most common in the glioblastomas; polysomy of
chromosome 7 (64%); focal amplification of the region
encompassing the EGFR receptor gene (44%); homo-
zygous deletion of the 9p21.3 region encompassing the
CDKN2A/14ARF and CDKN2B genes (32%); monosomy
chromosome 10 (65%); amplifications of 12q14-15 region
encompassing the CDK4 (11%) and MDM2 (9%) genes;
loss of the region encompassing the RB1 gene (27%); and
trisomy 19 (21%).
IDH1 and IDH2 mutation analysis
IDH1 mutation analysis identified mutation of codon
132 in 5/6 (83%) AOA, 36/43 (84%) AA and 40/232
(18%) of the successfully analysed GB in the series
(Table 1). IDH2 was analysed in all cases where no muta-
tions were found in IDH1 but was found in only 1/232 GB
patients. Survival by IDH1/2 mutation status is shown in
Figure 2.
Mutation analysis of TP53
Mutation analysis of exons 4–10 of TP53 was attempted
in 268 cases. This was not successful for all exons in a
significant number of cases due to limited amount of tem-
plate. However, the 82 cases with complete data showed
Table 1 Frequency of genetic abnormalities by tumour type
Tumour grade
AOA AA GB Total
N % N % N % N %
Chromosome 1 status
Normal copy number 3 50% 26 72% 127 56% 156 58%
Trisomy 0 0% 0 0% 4 2% 4 1%
Monosomy 0 0% 0 0% 0 0% 0 0%
Any other abnormality 3 50% 10 28% 94 42% 107 40%
1p status
Normal copy number 4 67% 28 78% 150 67% 182 68%
Loss of 1 copy 1 17% 1 3% 2 1% 4 1%
Any other abnormality 1 17% 7 19% 73 32% 81 30%
1p36 status
Normal copy number 4 67% 31 86% 161 72% 196 73%
Loss of 1 copy 1 17% 4 11% 49 22% 54 20%
Loss of both regions 0 0% 0 0% 6 3% 6 2%
Any other abnormality 1 17% 1 3% 9 4% 11 4%
Other abnormality
No 4 67% 28 78% 160 71% 192 72%
Yes 2 33% 8 22% 65 29% 75 28%
Chromosome 10 status
Normal copy number 4 67% 14 39% 24 11% 42 16%
Monosomy 0 0% 4 11% 146 65% 150 56%
10q partial deletion 2 33% 14 39% 45 20% 61 23%
Any other abnormality 0 0% 4 11% 10 4% 14 5%
PTEN
Normal copy number 6 100% 26 72% 54 24% 86 32%
Hemizygous deletion 0 0% 10 28% 162 72% 172 64%
Homozygous deletion 0 0% 0 0% 9 4% 9 3%
MGMT
Normal copy number 4 67% 15 42% 28 12% 47 18%
Hemizygous deletion 2 33% 21 58% 196 87% 219 82%
Homozygous deletion 0 0% 0 0% 1 0% 1 0%
6 100% 36 100% 225 100% 267 100%
Chromosome 7 status
Normal copy number 3 50% 22 61% 36 16% 61 23%
Trisomy/polysomy 0 0% 2 6% 143 64% 145 54%
Monosomy 0 0% 0 0% 1 0% 1 0%
Any other abnormality 3 50% 12 33% 45 20% 60 22%
Chromosome 19 status
Normal copy number 4 67% 26 72% 135 60% 165 62%
Trisomy 0 0% 4 11% 48 21% 52 19%
Monosomy 0 0% 0 0% 4 2% 4 1%
Any other abnormality 2 33% 6 17% 38 17% 46 17%
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Table 1 Frequency of genetic abnormalities by tumour type (Continued)
19q status
Normal copy number 4 67% 27 75% 139 62% 170 64%
Loss of 1 copy 1 17% 1 3% 2 1% 4 1%
Any other abnormality 1 17% 8 22% 84 37% 93 35%
19q13 status
Normal copy number 4 67% 27 75% 139 62% 170 64%
Loss of 1 copy 0 0% 3 8% 20 9% 23 9%
Any other abnormality 2 33% 6 17% 66 29% 74 28%
EGFR Amplification
No 6 100% 32 89% 125 56% 163 61%
Yes (>4 copies) 0 0% 4 11% 100 44% 104 39%
CDKN2A/p14ARF
Normal copy number 4 67% 24 67% 87 39% 115 43%
Hemizygous deletion 2 33% 11 31% 67 30% 80 30%
Homozygous deletion 0 0% 1 3% 71 32% 72 27%
MDM2 Amplification
No 6 100% 34 94% 205 91% 245 92%
Yes (>4 copies) 0 0% 2 6% 20 9% 22 8%
CDK4 amplification
No 6 100% 33 92% 200 89% 239 90%
Yes (>4 copies) 0 0% 3 8% 25 11% 28 10%
PDGFRA amplification
No 6 100% 33 92% 211 94% 250 94%
Yes (>4 copies) 0 0% 3 8% 14 6% 17 6%
RB1 copy number
Normal 5 100% 31 86% 164 73% 200 75%
Hemizygous deletion 0 0% 5 14% 60 27% 65 24%
3 copies 0 0% 0 0% 1 0% 1 0%
TP53 mutation cases with complete dataset only
No 2 40% 4 40% 43 64% 49 60%
Yes 3 60% 6 60% 24 36% 33 40%
IDH1/IDH2 mutation
No 1 17% 7 16% 191 82% 199 71%
Yes 5 83% 36 84% 41 18% 82 29%
RB1 pathway
Normal 3 60% 19 53% 52 23% 74 28%
Abnormal 2 40% 17 47% 173 77% 192 72%
p53 pathway
Normal 2 33% 2 7% 10 5% 14 6%
Abnormal 4 67% 26 93% 181 95% 211 94%
MGMT Methylation
<10% 0 0% 5 12% 66 28% 71 25%
≥10% 6 100% 36 88% 168 72% 210 75%
AOA, Anaplastic oligoastrocytoma; AA, Anaplastic Astrocytoma; GB, Glioblastoma.
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Figure 2 Survival by IDH1 mutation status. No IDH2 mutations were detected. Where DNA was available all cases without an IDH1 mutation
were pyrosequenced for the common IDH2 mutations. a) All glioblastoma (GB) and anaplastic astrocytoma (AA) patients only. Kaplan-Meier plots
of survival of patients who’s tumours had wild type IDH1 alleles and those with one mutated allele. b) Assessing the prognostic value of IDH1
mutation in AA and GB shows that in both tumour types mutation is associated with a better outcome.
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versus AA (6/10; 60%) and AOA (3/5; 60%) (see Table 1)
in accord with published data. In the 186 patients with
incomplete data mutations were found in a further 41 GB,
12 AA and one AOA patient. However as the data set was
incomplete it was not analysed further.
The p53 and RB pathways
In addition to the individual markers, a simple assess-
ment of the status of the RB1 and p53 pathways was
done (Table 1). Patients were considered to have a nor-
mal p53 pathway if CDKN2A/p14ARf, MDM2 and TP53
all had normal copy number, and to have an abnormal
p53 pathway if any one of these had any abnormality
(only copy number). Patients were determined to have anormal RB1 pathway if CDKN2A, CDK4 and RB1 had
normal copy number, and to have an abnormal RB1
pathway if any one of these had any copy number abnor-
mality. Disruption of each of these pathways was assessed
for prognostic or predictive relevance (Table 2). The lack
of comprehensive mutation data and methylation data for
all of the genes in these pathways will result in an under-
estimate of their disruption.
MGMT methylation data
A genomic map showing the region of the MGMT CpG
island analysed for methylation in this study by bisulfite
modification followed by pyrosequencing and the cor-
responding CpGs studied by some others is shown in
Figure 1 [2,3,22,23]. Initial analyses used the mean%
Table 2 Markers with independent prognostic value (Glioblastoma and Anaplastic Astrocytoma patients only)
Marker N HR (95% CI) p-value Overall p-value
Chromosome 1
Normal 153 - 0.358
Trisomy 4 0.92 (0.29-2.92) 0.885
Any other abnormality 104 1.22 (0.93-1.59) 0.157
1p status
Normal 178 - 0.828
Total loss of 1p 3 1.00 (0.24-4.10) 0.996
Any other abnormality 80 1.09 (0.82-1.45) 0.537
1p36 status
Normal 192 - 0.646
Loss of 1 copy 53 1.05 (0.75-1.45) 0.787
Loss of both copies 6 1.75 (0.76-4.05) 0.187
Any other abnormality 10 1.18 (0.57-2.42) 0.654
Chromosome 7
Normal 58 - 0.029
Monosomy 1 0.44 (0.06-3.35) 0.426
Trisomy 145 1.64 (1.11-2.42) 0.014
Any other abnormality 57 1.17 (0.77-1.79) 0.455
Chromosome 10
Normal 38 - 0.006
Monosomy 150 1.41 (0.91-2.19) 0.127
10q partial deletion 59 0.76 (0.48-1.21) 0.241
Any other abnormality 14 1.24 (0.58-2.65) 0.583
PTEN
Normal 80 - 0.001
Hemizygous deletion 172 1.85 (1.32-2.60) <0.001
Homozygous deletion 9 1.31 (0.62-2.81) 0.480
MGMT
Normal 43 - 0.776
Hemizygous deletion 217 1.05 (0.72-1.54) 0.797
Homozygous deletion 1 2.22 (0.30-16.56) 0.438
Chromosome 19
Normal 161 - 0.565
Monosomy 4 1.91 (0.69-5.25) 0.210
Trisomy 52 1.14 (0.82-1.60) 0.442
Any other abnormality 44 0.95 (0.66-1.36) 0.772
19q status
Normal 166 - 0.754
Total loss of 19q 3 1.10 (0.27-4.55) 0.898
Any other abnormality 92 1.11 (0.84-1.47) 0.454
19q13 status
Normal 166 - 0.643
Loss of 1 copy 23 0.99 (0.60-1.62) 0.968
Any other abnormality 72 1.15 (0.85-1.55) 0.355
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Table 2 Markers with independent prognostic value (Glioblastoma and Anaplastic Astrocytoma patients only)
(Continued)
EGFR
Normal 157 - 0.013
Amplified 104 1.42 (1.08-1.87) 0.013
CDKN2A
Normal 111 - 0.771
Hemizygous deletion 78 1.09 (0.79-1.51) 0.587
Homozygous deletion 72 1.12 (0.80-1.58) 0.500
MDM2
Normal 239 - 0.591
Amplified 22 1.13 (0.72-1.78) 0.586
CDK4
Normal 233 - 0.083
Amplified 28 1.46 (0.97-2.21) 0.070
PDGFRA
Normal 244 - 0.998
Amplified 17 1.00 (0.60-1.68) 0.997
Chromosome 13
Normal 184 - 0.760
Monosomy 37 1.15 (0.79-1.68) 0.460
Trisomy 1 0.86 (0.12-6.34) 0.886
Partial deletion 28 1.34 (0.85-2.11) 0.207
Any other abnormality 11 1.10 (0.53-2.28) 0.808
RB1 gene status
Normal 195 - 0.469
Hemizygous deletion 65 1.22 (0.89-1.66) 0.221
Homozygous deletion 1 0.86 (0.12-6.26) 0.878
RB1 pathway
Normal 71 - 0.061
Abnormal 190 1.35 (0.98-1.87) 0.066
TP53 mutation
No 47 - 0.296
Yes 83 0.80 (0.53-1.21) 0.293
p53 pathway
Normal 12 - 0.265
Abnormal 207 1.46 (0.73-2.91) 0.289
IDH1
Normal 198 - <0.001
Mutation 77 0.38 (0.26-0.56) <0.001
MGMT methylation
<10% 71 - <0.001
≥10% 204 0.45 (0.34-0.60) <0.001
Collins et al. Acta Neuropathologica Communications 2014, 2:68 Page 9 of 15
http://www.actaneurocomms.org/content/2/1/68methylation across all 16 CpGs to derive a single value
per patient, and classified those with <10% as low/
unmethylated and those ≥10% as high/methylated. This
was based on the approach taken by Dunn et al. [22]and the data reported by Malley et al. [19] and exa-
mination of Kaplan Meier survival plots with methyla-
tion grouped by 10% intervals supported this approach
(Figure 3) showing no evidence of a consistent linear
Figure 3 Kaplan-Meier plot of survival of all patients with anaplastic astrocytomas and glioblastomas by percentage methylation
averaged over the 16 CpGs analysed. Note that cases with average methylation levels of less than 10% differ markedly from those with greater
than 10% but increasing levels of methylation do not seem to have much impact on the survival curves.
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methylation. The 6 cases where there were specimens with
complete CpG data from two operations showed relatively
large variance in mean% methylation at each CpG but in
no case did the mean cross the 10% threshold, so all
tumours categorised as having methylation of MGMT at
the first operation (5/6 cases) were found to be methylated
at the second operation and visa versa.
Exploratory analyses of individual CpG methylation data
The best way to use the individual CpG methylation %s
is not known, but a simple average across all 16 gives
each CpG equal weight, and this may not be optimal.
Examination of the correlation coefficients for each CpG
with each of the other CpGs showed them all to be
highly correlated (data not shown) which suggests that
the prognostic value of methylation could be retained
using data from fewer CpGs. Each CpG was therefore
examined individually for its prognostic importance in
Cox regression models which retained the baseline clinical
factors and tumour grade (AA vs GB).
Analysing all eligible AA and GB patients (n = 269),
irrespective of the MGMT gene status, only 2 of the CpGs
were retained in the prognostic model, CpG 85 and 87
both with natural log transformations which suggested that
a binary cut-off point at 5-10% would also be appropriate.
Using bootstrap resampling to assess the robustness of the
model confirmed the importance of CpG 85 (retained in
87% of samples at a significance level of <0.01) but indi-
cated slightly more uncertainty for CpG 87 (retained in
79% of samples).Analysing the MGMT hemizygous patients only
(n = 203), a different model emerged with CpGs 75, 76
and 88 retained. However this model proved unstable
using the bootstrap resampling with none of these CpGs
retained in more than 60% of the samples. Repeating
these analyses in GB patients only, the MGMT hemizy-
gous subgroup again did not provide robust results but
retained CpG 75 in 67% of samples.
In view of the lack of stability of the models using
individual CpG data, the mean value across all CpGs
was included in the subsequent prognostic and predictive
models.
Clinical correlations
The association between each of the markers and the
baseline clinical variables was assessed. As expected, the
majority showed a clear association with tumour grade
(Table 1) in most cases GB tumours had higher rates of
abnormalities but 2 clear exceptions to this were TP53
and IDH1 mutations where the reverse was true. Ana-
lysis of the RB1 pathway showed an increased incidence
of abnormalities (as defined above) from 47% in AA to
77% in GB while abnormalities of the TP53 pathway
were present in 93% of AA and 95% of GB (the latter
were generally not due to TP53 mutations). With respect
to other clinical prognostic factors, normal PTEN copy
number, IDH1/2 mutation, TP53 mutation and loss of 1
copy of 19q13 were all associated with younger age,
while EGFR amplification, monosomy chromosome 10,
homozygous deletion of CDKN2A/p14ARF, and an abnor-
mal RB1 pathway were all associated with increased age.
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were associated with poorer performance status and
IDH1 mutation with better performance status.
There was an association between IDH1 mutations
and MGMT methylation (higher IDH1 mutation rates in
methylated tumours) across all tumour grades; this was
statistically significant (Fisher’s exact test, p <0.01) for
both AOA/AA and GB patients, but was most marked
in the AOAs and AAs. Among the 6 AOA tumours 5/6
had IDH1 mutations, and all 6 were judged to show
methylation of MGMT Considering only tumours where
we had results from both MGMT and IDH1/2 assays,
among the AA 34/39 were judged to have methylation
of MGMT and 31 of these 34 (91%) had IDH1 mutations.
Only 1/5 (20%) AA without methylation of MGMT had
an IDH1 mutation. Among the GBs with both results
available 153/215 were judged to show MGMT methy-
lation of which 36/153 (24%) had IDH1 mutations, while
IDH1 mutations were present in only 1/62 (2%) GBs with
no evidence of MGMT methylation. Similarly, there was
an association between IDH1 mutations, PTEN status and
tumour grade; a higher proportion of AA/AOA tumours
(36/41, 75%) were PTEN normal vs 52/211 (25%) GBs.
However, for both groups the IDH1 mutation rate was
higher in patients with normal copy number for PTEN
(51/82, 62%) than for PTEN hemi- or homozygous deleted
cases (17/169, 10%), p <0.001.
Prognostic markers
In view of the clinical associations noted above, each of
the potential markers was assessed first for its independ-
ent prognostic value in a Cox regression model which
included the baseline clinical characteristics (age, WHO
performance status, sex) as well as tumour grade (AA vs
GB; the small group with AOA tumours was excluded
from these analyses). Table 2 summarises the results of
these analyses showing that, individually, chromosome 7
and chromosome 10 copy number, EGFR amplification,
PTEN deletion, and mutated IDH1 was associated with
better prognosis. However when all these factors were
added to the base clinical model and a backwards step-
wise selection carried out for the non-clinical variables,
only IDH1 mutation retained independent statistical sig-
nificance (Table 3, model 1), indicating that, after account-
ing for tumour grade, age, sex and performance status,
IDH1 mutation was associated with better prognosis. In
view of the small number of patients in some categories, it
was not possible to look reliably at all possible interactions
within the Cox model, however interaction between IDH1
mutation and tumour grade was specifically examined;
Figure 2b shows that, while IDH1 mutations were much
more common in AA patients, they were also prognostic
for survival, and associated with a similar HR, in GB
patients (interaction p > 0.1).MGMT methylation (mean methylation <10% vs ≥10%)
was then introduced to the prognostic model. It retained
independent prognostic value (better prognosis associated
with methylation) when added directly to the best pre-
vious model (clinical variables plus IDH1 mutation,
see Table 3, model 2) and when included in the step-
wise model selection alongside all the factors that had
prognostic value independent of the clinical factors
(Table 3, model 3). However in the latter case, PTEN
copy number was retained in the model instead of IDH1
mutation. When the analyses were repeated in MGMT
hemizygous patients, the final model (Table 3, model 4)
again contained only the clinical variables, IDH1/2 muta-
tion andMGMT methylation status.
Predictive markers
Each of the potential markers was assessed for their
ability to predict benefit for temozolomide over PCV,
and of 21-day over 5-day TMZ. No evidence to support
a predictive role was found for any of the above markers
with the heterogeneity p value >0.1 in all cases. The bin-
ary methylation variable was also assessed as a predictor
of improved survival with TMZ over PCV and of 21-day
TMZ over 5-day TMZ. The hazard ratio plots are shown
in Figure 4 for all patients, and for the subset of patients
with hemizygous deletion of theMGMT gene. While there
was slightly greater evidence of interaction in the latter
group (benefit to TMZ over PCV being greater in patients
with higher methylation), there was no clear evidence that
MGMT methylation was predictive of benefit to TMZ
over PCV or of 21-day TMZ over 5-day TMZ. In keeping
with the results of the main trial, patients with MGMT
methylation showed a trend towards better survival on
5-day TMZ rather than 21-day.
Discussion
This study provides information on the incidence and
prognostic significance of a range of biomarkers in
patients with recurrent high-grade glioma in the setting
of a randomised trial that also allows for the assessment
of their potential predictive value. Although the study
aimed to assess biomarkers in all tumour specimens, the
practical reality, particularly in brain tumours and spe-
cifically high grade gliomas is that some samples are too
small for analysis due to the limited amount of tissue
which can be obtained by biopsy and the frequent pres-
ence of necrosis within the specimens. Nevertheless the
formalin fixed paraffin embedded material, which should
have been available from all patients who consented for
the molecular part of the study, allowed for a whole range
of modern techniques and provides a realistic picture
of the status of a variety of biomarkers of importance
in glial tumours. In addition there were no significant
differences in the patient and disease characteristics,
Table 3 Multivariate analyses
Factor HR (95% CI) (p value to exclude from model)
Model 1* (all pts) Model 2* (all pts) Model 3* (all pts) Model 4* (all pts)
Fixed variables
Age (years) 1.01 (0.99, 1.02) 1.01 (1.00, 1.02) 1.01 (1.00, 1.02) 1.00 (0.98, 1.02)
Tumour grade
III 1 1 1 1
IV 1.84 (1.10, 3.08) 2.25 (1.33, 3.83) 2.43 (1.48, 3.98) 1.53 (0.81, 2.92)
WHO Performance status
0 1 1 1 1
1 0.86 (0.58, 1.27) 0.93 (0.63, 1.39) 0.93 (0.63, 1.38) 0.79 (0.51, 1.21)
2 1.42 (0.93, 2.17) 1.63 (1.06, 2.53) 1.62 (1.05, 2.50) 1.39 (0.87, 2.22)
3 1.23 (0.69, 2.20) 1.54 (0.85, 2.81) 1.46 (0.93, 2.97) 1.64 (0.88, 3.06)
Gender
Male 1 1 1 1
Female 0.80 (0.59, 1.07) 0.82 (0.61, 1.10) 0.80 (0.57, 1.03) 0.91 (0.66, 1.25)
Additional independent factors
IDH1
Normal 1 1 1








Hemizygous deletion 1.83 (1.29, 2.61)
Homozygous deletion 1.47 (0.68, 3.16)
P = 0.003
MGMT methylation
<10% 1 1 1






*Model 1: mutation data only, final backwards stepwise selection model.
Model 2: addition of MGMT methylation status to Model 1.
Model 3: final backwards stepwise model including mutation data and MGMT methylation status.
Model 4: final backwards stepwise model including mutation data and MGMT methylation status, MGMT hemizygous deletion patients only.
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patients with assessable and unavailable tissue. All the
specimens were micro-dissected to ensure that almost
only tumour tissue was analysed, limiting the risk of nor-
mal DNA making the identification of genetic changes
more difficult, and the results are therefore truly represen-
tative of glioma tissue.
It must be stressed that the molecular analyses were
almost all carried out on tumour resected prior to radio-
therapy and that the tumours could have changed mo-
lecularly at the recurrence that resulted in the patient
being recruited to this trial. However, as discussed below,
the IDH mutation status and the MGMT methylation data
from the tumour at presentation were still found to be of
prognostic significance. In a small number of patients who
were operated on a number of times (data not shown) itwas possible to study a number of tumour specimens.
In all cases both the IDH status and the MGMT
methylation status remained constant despite an increase
in WHO grade.
The frequencies of the chromosomal region and gene
copy number abnormalities and the TP53 genes found
by sequencing, are broadly in accord with published data
[16,17,24-26], although the IDH1/2 mutation incidence
among the glioblastomas (18%) is higher than reported
in other studies. This may indicate a selection bias in the
cohort as patients were only eligible if they had a life
expectancy greater than 1 month, were fit for chemo-
therapy with adequate hepatic, renal and haematological
function [7]. These eligibility criteria would most likely
exclude older patients who generally have primary glio-
blastomas without IDH1/2 mutations. In addition a
Figure 4 An assessment of the predictive value of MGMT CpG island methylation in patients with all tumour types (AA,AOA and GB)
treated with standard (5-day) Temozolomide regime versus PCV and 5-day standard Temozolomide regime versus intensive (21-day)
temozolomide and the same analysis for those with monosomy chromosome 10 and thus only 1 MGMT copy.
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glioblastomas, having developed from astrocytomas or
anaplastic astrocytomas. Tumour location was not docu-
mented in the trial. The sequencing of TP53 on formalin
fixed paraffin embedded material proved difficult with a
limited number of cases being comprehensively analysed,
often due to limited template. Other examples of genetic
abnormalities found at commonly reported levels include
monosomy 10 found in 11% of the AA, but in 65% of the
GB, EGFR amplification found to be present in none of
the AOA, but in 11% of the AA and 44% of the GB and
homozygous deletion of CDKN2A/p14ARF/CDKN2B in 3%
of AA; 32% of GB. [17,26-30]. The full range of biomar-
kers analysed was examined for prognostic significance for
survival on univariate analysis; individually, chromo-
some 7 and chromosome 10 abnormalities, PTEN dele-
tion, EGFR amplification, IDH1/2 mutation and MGMT
methylation were all found to be of prognostic significance
independently of clinical variables. However, only IDH1/2
mutation (in one model replaced by PTEN status) and
MGMT methylation were independent prognostic factors
for survival when tested on multivariate analysis including
all clinical and molecular markers.
The study clearly demonstrates that in patients with
recurrent high-grade glioma treated with either TMZ or
PCV, IDH1/2 mutation and MGMT methylation levels
are of prognostic value independent of tumour grade
and of other clinical prognostic factors. While IDH1/2
mutations were substantially more common in AA pa-
tients (84% vs 18% of GB), in both groups they were
associated with significantly improved survival, with sur-
vival HRs of 3.82 (95% CI 1.08, 13.43) and 2.32 (95% CI
1.75, 3.19) respectively. This corroborates many previousstudies that have indicated the prognostic significance of
mutation of one allele of either the IDH1 or IDH2 genes;
patients with a mutation having a more favourable
outcome [10]. The same is true of the methylation data
presented [2]. It was also clear that there is a correlation
between IDH1/2 mutation and MGMT methylation and
also IDH1/2 mutation and PTEN status which is present
in both grade III tumours and primary glioblastomas [20].
Some studies of cultured cells have indicated that
tumours with wild type TP53 in addition to those with
MGMT methylation show increased sensitivity to alky-
lating agents, [31-34]. However, the incomplete data
set in this study does not permit an analysis of this
phenomenon.
CpG (cytosine-phosphate-Guanine) islands are genomic
regions with a concentration of CpGs in the DNA se-
quence. They frequently encompass the promoter region
and the first exon of genes and are intimately involved in
control of expression. Extensive methylation of CpGs in
such islands is generally associated with decreased expres-
sion. However, all of the CpGs in a particular island may
not have the same impact on expression when methylated
or unmethylated. Some may remain almost constantly
methylated affecting negligibly gene expression. In the
case of MGMT there are 98 CpGs in the island and a
number of studies have shown that while methylation of
CpGs 1–25 and 51–73 have little impact on expression,
methylation of CpGs 26–50 and 74–92 have [19,35]. Most
studies have analysed the region 74–92 as is the case here
[1-3,22]. The problem when using the findings for thera-
peutic decision-making is examining efficiently as many
CpGs as are necessary to provide a clinically depend-
able and relevant answer for an individual patient. Some
Collins et al. Acta Neuropathologica Communications 2014, 2:68 Page 14 of 15
http://www.actaneurocomms.org/content/2/1/68analytical methods examine only one CpG while others
analyse varying numbers of CpGs (see [36-38] for reviews).
There are a number of analytic approaches to the
assessment of MGMT methylation when data from indi-
vidual CpGs is available. Our primary analyses replicated
previous work, in taking an average value across all
CpGs and dividing patients into those with low (<10%)
or high (≥10%) methylation [22]. Based on this approach,
we found MGMT methylation to be of independent prog-
nostic value (over and above clinical factors and IDH1/2
mutation) but did not find clear evidence of a predictive
effect in terms of distinguishing patients most likely to
respond to TMZ over PCV. This was also the case when
analyses were restricted to patients with hemizygous dele-
tion of MGMT. While this might be expected given the
presence of alkylating agents in both arms, it must also be
acknowledged that power to detect modest interactions is
low, and the potential for MGMT methylation to distin-
guish responders to TMZ over PCV, as it does for TMZ
over no TMZ [2] cannot be excluded based on this study.
Reducing inherently continuous data, such as MGMT
methylation, into binary (methylated/unmethylated) is not
generally statistically efficient, and so in our exploratory
analyses considering the individual CpGs we used the
continuous data, and fitted models that allowed flexibility
in the shape of any relationship between methylation%
and outcome beyond a simple linear relationship. Using
all patients, irrespective of MGMT copy number, CpGs 85
and 87 showed independent prognostic value (higher
methylation conferring better prognosis) with best fit
achieved using the natural log of methylation in each case;
this can be interpreted as supporting a binary cut off as a
sufficiently efficient way to summarise the data. However,
when this analysis was repeated in MGMT hemizygous
patients, an adequately stable model could not be found.
Quillien et al. have presented data suggesting that CpG 77
is most significant [3] while Malley found mutation of
CpG 89 to have the most marked effect on expression by
a luciferase reporter construct [19].
Total loss of one copy of 1p and 19q is uncommon in
anaplastic astrocytomas and glioblastomas, as was found
in this study (1/36 AAs and 2/225 GB). However, hemi-
zygous loss of 1p36 is much more common (AAs 11%;
GBs 22%) and homozygous deletion of this area also
occurs in some glioblastomas (3% in this study). How-
ever, while the incidence of losses in this area increased
with malignancy grade, we found no evidence that this
finding might represent a prognostic or a predictive
biomarker.
In summary, in the largest randomised trial in chemo-
naïve patients with recurrent high grade glioma we were
able to demonstrate the independent prognostic signifi-
cance of IDH1/2 and MGMT methylation status, and
potentially PTEN status, for survival. While individualCpGs methylation data has the potential to replace over-
all mean values, we were not able to find a sufficiently
stable model on which to base recommendations. The
findings further support the argument that future trials
in recurrent disease which are used as an indicator of ef-
ficacy of novel agents will need to stratify patients by all
the known clinical prognostic factors and they must in-
clude MGMT and IDH1/2 status.
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